Pharmaceuticals
Innovent Receives NMPA Breakthrough Designation for IBI310, the Anti-CTLA-4 Monoclonal Antibody, Combined with Sintilimab in Advanced Cervical Cancer Treatment
SAN FRANCISCO and SUZHOU, China, April 14, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other majo...
2022-04-14 08:30
6813
TauRx's late-stage clinical trial reaches new milestone
- Significant milestone in the only late-stage clinical trial targeting tau pathology of Alzheimer's - TauRx on track to announce top line results in May - Trial aims to confirm efficacy of first tau-based treatment for Alzheimer's ABERDEEN, Scotland and SINGAPORE, April 14, 2022 /PRNewswire/ -...
2022-04-14 08:17
2487
Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW004, an oral tablet formulation of its Proprietary GLP-1 Analogue (Ecnoglutide)
HANGZHOU, China and SAN FRANCISCO, April 14, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the initiation of subject dosing in its Phase 1 clinic...
2022-04-14 08:00
3150
Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders
Insilico Medicine Nominates Its USP1 Small Molecule Inhibitor as a Preclinical Candidate for Tumors with Homologous Recombination Deficiency NEW YORK, April 13, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery com...
2022-04-13 23:00
4591
European Wellness Signs MOU in Dubai Expo 2020 to Strengthen Medical Tourism into Malaysia and Develop Advanced Biological Regenerative Medicine in UAE
DUBAI, UAE, April 13, 2022 /PRNewswire/ -- European Wellness Biomedical Group (EW Group), through its Malaysian subsidiary European Wellness Academie, and Dubai- based healthcare distribution and technology group, AK International LLC, have signed a Memorandum of Understanding (MOU) on 30th March ...
2022-04-13 21:38
4261
Ascletis Announces Cooperation with China Meheco International Co., Ltd. in Distribution of Its Ritonavir Tablets in Chinese Mainland
HANGZHOU, China and SHAOXING, China, April 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Ascletis Pharmaceuticals Co., Ltd. ("Ascletis Pharmaceuticals") has signed an agreement with China Meheco International Co., Ltd. for distribution of its ritonavi...
2022-04-13 21:00
4223
CStone Announces Presentation of Preclinical data on a Multi-Specific Antibody-based Therapeutic Candidate CS2006/NM21-1480 at the American Association for Cancer Research (AACR) Annual Meeting 2022
* Results from pharmacokinetic/pharmacodynamic modeling demonstrated that binding affinity optimization of CS2006/NM21-1480 allowed optimal PD-L1 blockade and 4-1BB stimulation concomitantly, at a broad dose range thereby and facilitating dose-finding in the clinic * CS2006/NM21-1480 was effi...
2022-04-13 08:02
3421
Cambrex Completes Large-Scale US API Expansion
EAST RUTHERFORD, N.J., April 13, 2022 /PRNewswire/ -- Cambrex announced today the completion of a$50 million expansion of its large-scale active pharmaceutical ingredient (API) manufacturing capabilities at itsCharles City, Iowa facility. The startup of the new manufacturing space is the culminat...
2022-04-13 06:50
1912
Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
ROSCREA, Ireland, April 12, 2022 /PRNewswire/ -- Renexxion Ireland Ltd., a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal ("GI") disorders, announced today that it has entered into a share subscription agreement with...
2022-04-12 20:00
2073
The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of Small Cell Lung Cancer Accepted by NMPA
SHANGHAI, April 11, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of HANSIZHUANG (serplulimab), a novel anti-PD-1 monoclonal antibody (mAb) independently developed by the company, in combination with chemotherapy for the first-line tr...
2022-04-11 22:07
3359
Global pharma organizations back Turn Biotechnologies to advance its cell rejuvenation program
Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management and other VCs in oversubscribed funding round to accelerate Turn Bio's preclinical advances in multiple therapeutic areas MOUNTAIN VIEW, Calif., April 11, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation com...
2022-04-11 19:00
2557
APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial
BOSTON, April 11, 2022 /PRNewswire/ -- APRINOIA Therapeutics announces today that the U.S. Food and Drug Administration (FDA) has granted a may proceed authorization for its novel therapeutic anti-tau monoclonal antibody, APNmAb005, allowing the company to test and evaluate its safety in healthy ...
2022-04-11 18:00
3123
Successful Passing Of The EU Qualified Person Audit Of The Group's Manufacturing Facility For ReCOV In Taizhou
TAIZHOU, China, April 11, 2022 /PRNewswire/ -- The board of directors of Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group",Stock code:2179.HK) is pleased to announce that, on April 9, 2022, the Company has received the European Union (EU) Qualified Pe...
2022-04-11 16:05
3364
Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting
The company will present the preclinical data of five novel drug candidates at AACR 2022 (onApril 8-13). Focus on ATG-037, ATG-018, ATG-022, ATG-012 and ATG-008. SHANGHAI and HONG KONG, April 11, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovativ...
2022-04-11 08:30
4290
Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 bispecific antibody) in patients with advanced solid tumors at AACR Annual Meeting 2022
SAN FRANCISCO and SUZHOU, China, April 11, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...
2022-04-11 08:14
3608
Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab
MELBOURNE, Australia and INDIANAPOLIS, April 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, "Telix", the "Company") today announces that it has entered into a licence agreement with Eli Lilly and Company ("Lilly") under which Telix is granted exclusive worldwide rights to devel...
2022-04-11 06:51
3202
Gannex Announces First Patient Dosed in Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis
-- Gannex is expected to complete the Phase II trial in 100 patients by the end of 2022. -- Gannex intends to soon start a Phase III trial in China, the U.S. and European Union after the completion of the Phase II study inChina. -- An epidemiology study in China in 2010 showed that there were a...
2022-04-10 18:20
2680
Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene
BEIJING, April 8, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced that they have reached an agreement with BeiGene (Beijing) Co., Ltd. ("BeiGene") (NASDAQ code: BGNE; Hong Kong Stock Exchange code: 06160; Shanghai Stock Exchange code: 688235)on March 10, for licensin...
2022-04-08 21:00
6859
Novavax and Serum Institute of India Receive Emergency Use Authorization for Novavax' COVID-19 Vaccine in Thailand
GAITHERSBURG, Md., and PUNE, India, April 8, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine ...
2022-04-08 21:00
5901
Henlius' Serplulimab Granted Orphan-Drug Designation in the United States for Small Cell Lung Cancer
SHANGHAI, April 7, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the United States Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) for HANSIZHUANG (serplulimab) for the treatment of small cell lung cancer (SCLC). This is the first such d...
2022-04-07 22:21
4303
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 317 media titles]
2026-09-03 23:53
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 312 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 311 media titles]
2026-09-02 08:30Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 307 media titles]
2026-09-01 11:00
DayOne and TNB Explore Up To 1.5 GW of On-Site Power Generation to Advance Malaysia's Energy Resilience and Digital Economy
[Picked up by 292 media titles]
2026-09-01 17:36Most Read
Klook Takes Creator Commerce Beyond Influence With Kreator Shops
2026-09-01 11:00
7146
YY Group Enters New Era as YYForce, Expanding AI, Automation and Human-Robot Workforce Strategy; Nasdaq Ticker Changes to "YFOR"
2026-09-01 04:10
6914
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
2026-09-02 12:17
6708
